Most individuals with SBCADD are identified through newborn screening, where they present with an elevation of a five carbon acylcarnitine species.
mˈoʊst ˌɪndᵻvˈɪdʒuːəlz wɪð ˌɛsbˈiːkˈæd ɑːɹ aɪdˈɛntᵻfˌaɪd θɹuː nˈuːbɔːɹn skɹˈiːnɪŋ, wˌɛɹ ðeɪ pɹɪzˈɛnt wɪð ɐn ˌɛlɪvˈeɪʃən əvə fˈaɪv kˈɑːɹbən ɐkˈɪlkɑːɹnˌɪtiːn spˈiːsiːz.